Skip to main content

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.

Publication ,  Journal Article
Reardon, DA; Egorin, MJ; Quinn, JA; Rich, JN; Gururangan, S; Vredenburgh, JJ; Desjardins, A; Sathornsumetee, S; Provenzale, JM; Herndon, JE ...
Published in: J Clin Oncol
December 20, 2005

PURPOSE: We performed a phase II study to evaluate the combination of imatinib mesylate, an adenosine triphosphate mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a ribonucleotide reductase inhibitor, in patients with recurrent glioblastoma multiforme (GBM). PATIENTS AND METHODS: Patients with GBM at any recurrence received imatinib mesylate plus hydroxyurea (500 mg twice a day) orally on a continuous, daily schedule. The imatinib mesylate dose was 500 mg twice a day for patients on enzyme-inducing antiepileptic drugs (EIAEDs) and 400 mg once a day for those not on EIAEDs. Assessments were performed every 28 days. The primary end point was 6-month progression-free survival (PFS). RESULTS: Thirty-three patients enrolled with progressive disease after prior radiotherapy and at least temozolomide-based chemotherapy. With a median follow-up of 58 weeks, 27% of patients were progression-free at 6 months, and the median PFS was 14.4 weeks. Three patients (9%) achieved radiographic response, and 14 (42%) achieved stable disease. Cox regression analysis identified concurrent EIAED use and no more than one prior progression as independent positive prognostic factors of PFS. The most common toxicities included grade 3 neutropenia (16%), thrombocytopenia (6%), and edema (6%). There were no grade 4 or 5 events. Concurrent EIAED use lowered imatinib mesylate exposure. Imatinib mesylate clearance was decreased at day 28 compared with day 1 in all patients, suggesting an effect of hydroxyurea. CONCLUSION: Imatinib mesylate plus hydroxyurea is well tolerated and associated with durable antitumor activity in some patients with recurrent GBM.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

December 20, 2005

Volume

23

Issue

36

Start / End Page

9359 / 9368

Location

United States

Related Subject Headings

  • Survival Analysis
  • Pyrimidines
  • Piperazines
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Imatinib Mesylate
  • Hydroxyurea
  • Humans
  • Glioblastoma
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reardon, D. A., Egorin, M. J., Quinn, J. A., Rich, J. N., Gururangan, S., Vredenburgh, J. J., … Friedman, H. S. (2005). Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol, 23(36), 9359–9368. https://doi.org/10.1200/JCO.2005.03.2185
Reardon, David A., Merrill J. Egorin, Jennifer A. Quinn, Jeremy N. Rich, Sridharan Gururangan, James J. Vredenburgh, Annick Desjardins, et al. “Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.J Clin Oncol 23, no. 36 (December 20, 2005): 9359–68. https://doi.org/10.1200/JCO.2005.03.2185.
Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005 Dec 20;23(36):9359–68.
Reardon, David A., et al. “Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.J Clin Oncol, vol. 23, no. 36, Dec. 2005, pp. 9359–68. Pubmed, doi:10.1200/JCO.2005.03.2185.
Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005 Dec 20;23(36):9359–9368.

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

December 20, 2005

Volume

23

Issue

36

Start / End Page

9359 / 9368

Location

United States

Related Subject Headings

  • Survival Analysis
  • Pyrimidines
  • Piperazines
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Imatinib Mesylate
  • Hydroxyurea
  • Humans
  • Glioblastoma